Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Regencells Biomedical Co. Ltd. is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution activity is localized in 1 distinct art unit, showing a specific technical focus for the pending matter. The data identifies 1 distinct examiner assigned to the portfolio, which centralizes the current examination process.
ABEYRATNE-PERERA, HASHANTHI KOMITIGE is the busiest examiner for this entity, currently managing 1 pending office action. As the only examiner involved, ABEYRATNE-PERERA, HASHANTHI KOMITIGE is responsible for the full scope of the company's 1 pending office action. The concentration in 1 distinct art unit indicates that the patent application falls under a specific classification within the Biotechnology & Pharmaceuticals sector.
The presence of 1 distinct examiner allows the prosecution strategy to be tailored to the specific requirements and feedback of that individual. This streamlined interaction within the patent office allows for a focused legal response to the 1 pending office action managed by the busiest examiner. The data reflects a precise and narrow engagement with the office for the current assets.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABEYRATNE-PERERA, HASHANTHI KOMITIGE | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18494879 | METHOD FOR CULTURING AND EXPANDING NUCLEUS PULPOSUS CELLS DERIVED FROM INTERVERTEBRAL DISCS AND FOR IMPROVING LOWER BACK PAIN USING NUCLEUS PULPOSUS CELLS | ABEYRATNE-PERERA, HASHANTHI KOMITIGE | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18494879 | METHOD FOR CULTURING AND EXPANDING NUCLEUS PULPOSUS CELLS DERIVED FROM INTERVERTEBRAL DISCS AND FOR IMPROVING LOWER BACK PAIN USING NUCLEUS PULPOSUS CELLS | ABEYRATNE-PERERA, HASHANTHI KOMITIGE | 1632 | §103 | Non-Final OA | — | Pending | Oct 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRegencells Biomedical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Hashanthi Komitige Abeyratne-Perera has the most, with 1 of Regencells Biomedical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
